Download

Download Full Text (269 KB)

Document Type

Poster

Description

Children who have been infected with Respiratory Syncytial Virus have a higher incidence of wheeze-associated clinic visits and hospitalizations compared to children without previous RSV exposure. The purpose of this study is to determine if palivizumab, an immunoglobulin injection used to prevent RSV infections, can decrease the incidence of recurrent wheezing in children. The review of literature will follow male and female children from infancy to age 13 who were treated with palivizumab and compare these children to patients with similar demographics that were not treated with palivizumab to determine if there is any difference in incidence of wheezing. The anticipated results are that patients treated with palivizumab will have a decreased incidence of recurrent wheeze. The findings may indicate that prevention of RSV with palivizumab will improve long-term health in children.

Department

Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

First Advisor

Vikki McCleary

Publication Date

2014

Keywords

Antibodies, Monoclonal -- therapeutic use; Bronchiolitis, Viral -- prevention & control; Child; Infant; Palivizumab -- therapeutic use; Respiratory Sounds; Respiratory Syncytial Virus Infections -- complications

Disciplines

Medical Immunology | Respiratory Tract Diseases

Palivizumab Administration Decreases Recurrent Wheeze

Share

COinS